Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Myriad Genetics (MYGN)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for MYGN as compared to
Top Competitors
Diagnostic Substances
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS
No data.
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
338M
AVG
EBITDA
►
134M
HIGH
Net Income
►
101M
HIGH
Revenue Growth
►
-5.9%
AVG
Net Income Growth
►
43%
AVG
Operating Margin
►
38%
AVG
Net Margin
►
45%
HIGH
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
0.0444
VERY LOW
Current Ratio
►
19.5
VERY HIGH
Quick Ratio
►
19.5
VERY HIGH
Book Value Per Share
►
4.91
Cash Per Share
►
0.947
Loading...
STOCK SUMMARY
Open
23.65
Day Range
23.62
-
24.06
52 Week Range
22.38
-
44.90
Volume
1.31M
Avg Volume (3 mo)
1.54M
Shares Outstanding
96.7M
Market Cap
2.29B
VALUATION
Price to Earnings (P/E)
►
15.4
AVG
Price to Book (P/B)
►
4.96
AVG
Price to Sales (P/S)
►
6.94
AVG
Return on Assets (ROA)
►
19.6%
HIGH
Return on Equity (ROE)
►
21.2%
AVG
EV/EBITDA
►
18.1
AVG
Dividend Yield
0%
AVG
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
-9%
Net Insider Buying 6mo
-11.2%
Net Insider Buying 1yr
-23.9%
Held by insiders
1.5%
Held by institutions
68.3%
No Sales Breakout Data.